Qin et al[5] recently reported that a female lung adenocarcinoma patient with brain metastases and the coexistence of an EGFR mutation/DCTN1-ALK translocation responded well to successive osimertinib and alectinib treatment. This evidence concerns the gene ALK and lung adenocarcinoma.